Heart Disease at 30, AI-Discovered Cures, and Reversed Alzheimer’s: Longevity Medicine’s Landmark Week

For decades, the prevailing model of medicine was fundamentally reactive: wait for disease to manifest, then treat it. That model is breaking down with remarkable speed. In just the past few weeks, three landmark developments have emerged that, taken together, suggest we are crossing a threshold where the diseases that have defined human aging are being pushed back not just in time, but in kind.

Presented By Our Partners

New clinical guidelines now recommend that cardiovascular disease prevention begin at age 30. An AI system trained on millions of gene expression measurements has discovered promising drug candidates for two diseases that previously had no curative options. And a compound that restores the cellular energy molecule NAD+ has fully reversed advanced Alzheimer’s disease in animal models. Each finding, on its own, would be significant. Together, they signal a new era in longevity medicine, one defined by prediction, acceleration, and reversal.

Rethinking Heart Disease: The Case for Earlier Action

On March 13, 2026, the American College of Cardiology and American Heart Association, joined by nine additional medical societies, released the most sweeping update to cholesterol and lipid management guidelines in years. Published simultaneously in the Journal of the American College of Cardiology and Circulation, the 2026 ACC/AHA Guideline on the Management of Dyslipidemia represents a fundamental shift in how medicine approaches cardiovascular risk across a lifetime.

The headline change: statin therapy is now worth considering for adults as young as 30. Led by writing committee chair Roger Blumenthal, MD, director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, and vice chair Pamela B. Morris, MD, the guideline committee determined that waiting until middle age to address elevated LDL cholesterol means accepting years of arterial damage that accumulates silently. For adults aged 30 and older with LDL-C of 160 mg/dL or greater, a strong family history of premature cardiovascular disease, or high 30-year risk as calculated by the new PREVENT equations, earlier intervention is now the evidence-backed recommendation.

The guidelines also introduce a universal recommendation that is long overdue: every adult should have their lipoprotein(a), or Lp(a), measured at least once in their lifetime. Lp(a) is a genetically determined form of cholesterol that standard lipid panels miss entirely. High Lp(a), defined as 125 nmol/L or greater, is associated with approximately a 1.4-fold increased long-term risk of heart attack or stroke, entirely independent of LDL. The new guidance acknowledges that millions of people carry a measurable but invisible risk factor they have simply never been told about.

New LDL targets are more aggressive as well: below 100 mg/dL for those at borderline or intermediate risk, below 70 mg/dL for high-risk individuals, and below 55 mg/dL for those at very high risk with existing arterial disease. The PREVENT risk calculator, validated for adults ages 30 through 79, provides personalized 10-year and 30-year risk estimates that account for far more variables than previous tools. Apolipoprotein B (ApoB) testing and coronary calcium scoring are now formally supported as complementary tools for finer-grained risk stratification.

The practical implication is profound. Cardiovascular disease remains the leading cause of death globally. By the time a patient presents with a first heart attack, typically in their 50s or 60s, decades of preventable arterial damage have already accumulated. These guidelines are medicine’s formal acknowledgment that genuine longevity requires acting on the biology of disease long before symptoms ever appear.

When AI Reads the Language of Genes

In parallel with these clinical developments, a team at Michigan State University has demonstrated a fundamentally new kind of drug discovery: one where an AI system learns the molecular language of gene expression well enough to predict, from a compound’s chemical structure alone, how that compound will alter gene activity inside living cells.

The study, published in Cell in March 2026 (DOI: 10.1016/j.cell.2026.02.016), was led by Jing Xing and colleagues, with senior authors including Jiayu Zhou, PhD, formerly of MSU and now at the University of Michigan, and Xiaopeng Li, PhD, associate professor in the Department of Pediatrics and Human Development at MSU’s College of Human Medicine. Their platform, named GPS (Gene expression profile Predictor on chemical Structures), was trained on millions of experimental measurements linking chemical structures to their downstream effects on gene expression patterns across diverse cell types.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The team deployed GPS against two diseases that define the outer limits of what current medicine can address. The first: hepatocellular carcinoma, the most aggressive form of liver cancer and the third-leading cause of cancer-related death worldwide. The second: idiopathic pulmonary fibrosis, or IPF, a chronic and progressive scarring of the lungs that carries a median survival of just three years after diagnosis and, until now, no curative treatment options.

The results were striking. Against hepatocellular carcinoma, GPS identified two new compounds that, when tested in mice, significantly reduced tumor size. Against IPF, the platform identified one repurposed drug already approved for other indications, plus two entirely new compounds, all showing meaningful efficacy in preclinical models. In a gesture toward open science, the team released the GPS code and launched a web-based portal allowing other researchers to apply the approach to additional diseases.

What GPS represents is more than a faster version of traditional drug screening. It is a different kind of biological intelligence: a system that understands disease at the level of transcriptomic signatures, the characteristic patterns of gene activity that define what a diseased cell is doing and what a healthy cell should be doing instead. By learning to predict those signatures from chemistry alone, GPS can effectively reverse-engineer the molecular intervention needed to shift a cancer cell or a fibrotic cell back toward healthy function. This is generative medicine in action, and it is now producing results that are entering the translational pipeline.

The NAD+ Connection: Reversing What Was Thought Irreversible

Perhaps the most striking finding of the past several weeks comes from Case Western Reserve University and University Hospitals, where a team published results in Cell Reports Medicine that challenge one of the deepest assumptions in all of neurology: that Alzheimer’s disease, once advanced, cannot be reversed.

The study, published online December 22, 2025, was led by Kalyani Chaubey and Edwin Vázquez-Rosa, with senior author Andrew A. Pieper, MD, PhD, of Case Western Reserve University. Rather than targeting amyloid plaques or tau tangles directly, as most previous Alzheimer’s therapies have attempted, their compound, P7C3-A20, works upstream at the level of cellular energy metabolism. Specifically, it restores the brain’s supply of nicotinamide adenine dinucleotide (NAD+), the central molecule driving energy production, DNA repair, and anti-inflammatory signaling throughout the body.

NAD+ is essential to dozens of interconnected biological processes, including mitochondrial function, oxidative stress regulation, and the signaling cascades that govern inflammation. As cells age under chronic stress, NAD+ homeostasis deteriorates. In Alzheimer’s disease, this disruption is severe. Prior work from the Pieper laboratory established that pathology severity in both mice and humans correlates tightly with the degree of NAD+ disruption in brain tissue, suggesting the energy crisis is not a byproduct of the disease but a central driver of it.

When P7C3-A20 was administered to 5xFAD mice with advanced, amyloid-driven Alzheimer’s disease, the results were extraordinary. The compound reversed tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation simultaneously. It enhanced hippocampal neurogenesis and synaptic plasticity. Most significantly, the mice achieved full cognitive recovery, not a slowing of decline, but a genuine return to normal cognitive function. Plasma levels of p-tau217, a clinical biomarker of Alzheimer’s severity now used in human diagnostics, normalized as well.

The same results were replicated in PS19 mice, a model driven by tau pathology rather than amyloid, suggesting the mechanism operates independently of any single disease pathway. Critically, the researchers identified 46 proteins in the mouse brain that were abnormally expressed in advanced Alzheimer’s and fully normalized by P7C3-A20. Those same 46 proteins show comparable alterations in human Alzheimer’s brain tissue, providing a precise mechanistic bridge between mouse and human pathology. The technology is being commercialized by Glengary Brain Health, a Cleveland-based company co-founded by Pieper, with human clinical trials as the next milestone.

The Cellular Thread That Connects All Three

These three stories, spanning cardiology, computational biology, pulmonology, and neurology, converge on a single underlying principle: the diseases that shorten human lives are not random. They are the downstream consequences of cellular processes that go wrong in predictable, detectable, and increasingly modifiable ways.

NAD+ runs as a connecting thread through all three domains. In cardiovascular disease, NAD+ depletion drives endothelial dysfunction and vascular inflammation, the precise biological processes the new lipid guidelines attempt to arrest by reducing cumulative LDL exposure earlier in life. In cancer and fibrosis, disrupted cellular energy metabolism is both a hallmark of disease and a therapeutic vulnerability. In neurodegeneration, restoring NAD+ homeostasis appears sufficient, at least in animal models, to reverse years of accumulated brain damage.

Across the six longevity pillars that define the Healthcare Discovery framework, the pattern is consistent. The Cardiology pillar now has new, evidence-backed tools for earlier risk stratification, including universal Lp(a) measurement and the PREVENT calculator. The Cellular Health pillar, which encompasses mitochondrial function, senolytics, and epigenetic aging, is precisely the domain where NAD+ research operates. The Pulmonary pillar now has, for the first time, AI-discovered candidates specifically targeting idiopathic pulmonary fibrosis. And the Neurology pillar, long dominated by a string of late-stage clinical failures, has a mechanistic direction pointing toward reversal rather than mere preservation.

What unites these developments is a systems-level shift in how medicine conceptualizes disease. The old model treated each organ system in isolation and waited for pathology to announce itself before acting. The emerging model recognizes that the same molecular substrates, among them NAD+ metabolism, lipid accumulation over decades, and gene expression dysregulation, underlie aging across every tissue simultaneously. Address the substrate, and the downstream pathologies become approachable in ways they never were before. That is the deep promise of longevity biology as a discipline: targeting root causes rather than managing symptoms.

What This Means for You

The practical takeaway from this week’s developments is both urgent and actionable. Ask your doctor about Lp(a) testing if you have never had it: the new ACC/AHA guidelines recommend it at least once in adulthood, and the test is widely available. If you are under 40 and carry a family history of early heart disease or elevated LDL, a conversation about the PREVENT calculator and earlier lipid management is now backed by the full weight of ACC/AHA evidence. Optimize the four fundamentals of energy (nutrition, sleep, movement, and breath) to support your body’s own NAD+ production and cellular resilience. And if Alzheimer’s disease runs in your family, follow the work of the Pieper Laboratory closely: the translation of the NAD+ reversal findings into human trials may represent one of the most consequential therapeutic developments in neurological medicine in a generation.

The Road Ahead

Ray Kurzweil has long predicted that humanity is approaching what he calls Longevity Escape Velocity: the point at which science extends healthy life faster than time takes it away. Whether that threshold arrives on his timeline or later, the trajectory is unmistakable. In a single month, cardiovascular guidelines have moved active prevention a decade earlier in life, an AI system has compressed the drug discovery timeline for two deadly diseases from years to months, and a compound has restored full cognitive function in animals with advanced brain disease. The biology of aging is being mapped at a resolution that was unimaginable a decade ago, and the map is pointing unmistakably toward intervention rather than management. The question for the years ahead is no longer whether we can meaningfully slow and reverse the diseases of aging. The question is how quickly the tools now being validated in research laboratories will reach the people who need them most.

Sources:
Blumenthal RS, Morris PB, et al., 2026 ACC/AHA Guideline on the Management of Dyslipidemia, Circulation, 2026
2026 Dyslipidemia Guideline-at-a-Glance, Journal of the American College of Cardiology, 2026
American Heart Association, ACC/AHA Issue Updated Guideline for Managing Lipids and Cholesterol, March 13, 2026
Jing Xing et al., Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes, Cell, 2026 (DOI: 10.1016/j.cell.2026.02.016)
Michigan State University College of Human Medicine, MSU study demonstrates faster discovery of therapeutic drugs through AI, March 2026
Kalyani Chaubey, Edwin Vázquez-Rosa, Andrew A. Pieper et al., Pharmacologic reversal of advanced Alzheimer’s disease in mice and identification of potential therapeutic nodes in human brain, Cell Reports Medicine, December 2025
Case Western Reserve University, New study shows Alzheimer’s disease can be reversed to achieve full neurological recovery, December 2025

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.